Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HPV-CTLs in the Treatment of HPV Infection
NCT03351855Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of HPV-specific cytotoxic T lymphocytes in human papillomavirus infection, sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of HPV-CTLs at 6 months. Started Jun 2026; status: terminated.
02
Drugs
HPV-specific cytotoxic T lymphocytes
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT03351855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351855.